trelagliptin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dipeptidyl aminopeptidase-IV inhibitors 5013 865759-25-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • TAK-472
  • trelagliptin
  • trelagliptin succinate
  • SYR-472
  • SYR111472
  • zafatek
Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus.
  • Molecular weight: 357.39
  • Formula: C18H20FN5O2
  • CLOGP: 1.13
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 93.67
  • ALOGS: -3.22
  • ROTB: 3

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 26, 2015 PMDA Takeda

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

None

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.4 Basic
pKa2 1.33 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Dipeptidyl peptidase 4 Enzyme INHIBITOR IC50 8.40 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
D10178 KEGG_DRUG
1029877-94-8 SECONDARY_CAS_RN
C4045914 UMLSCUI
CHEBI:134715 CHEBI
6RL PDB_CHEM_ID
CHEMBL1650443 ChEMBL_ID
CHEMBL2105754 ChEMBL_ID
C000595449 MESH_SUPPLEMENTAL_RECORD_UI
9556 INN_ID
DB15323 DRUGBANK_ID
Q836OWG55H UNII
15983988 PUBCHEM_CID

Pharmaceutical products:

None